We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-10.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.15B
AUM Growth
-$1.56B
Cap. Flow
-$673M
Cap. Flow %
-16.21%
Top 10 Hldgs %
47.21%
Holding
133
New
21
Increased
21
Reduced
31
Closed
23

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$71.4M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$45.8M
3
IMTX icon
Immatics
IMTX
+$39.5M
4
CTNM
Contineum Therapeutics
CTNM
+$25.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$19M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$149M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$146M
3
MDT icon
Medtronic
MDT
+$77M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$68.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$47.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXRX icon
76
Recursion Pharmaceuticals
RXRX
$1.74B
$5.77M 0.14%
+769,230
New +$6.71M
EYPT icon
77
EyePoint Inc
EYPT
$316M
$5.57M 0.13%
640,274
+50,628
+9% +$707K
IMVT icon
78
CALL
Immunovant
IMVT
$7.57B
$5.28M 0.13%
200,000
+100,000
+100% +$2.84M
BBOT
79
BridgeBio Oncology
BBOT
$391M
$5.11M 0.12%
500,000
– –
MREO
80
Mereo BioPharma
MREO
$45.5M
$4.51M 0.11%
+1,253,250
New +$4.06M
CABA icon
81
Cabaletta Bio
CABA
$441M
$4.38M 0.11%
585,045
-1,131,615
-66% -$13.9M
DTIL icon
82
Precision BioSciences
DTIL
$182M
$4.15M 0.1%
426,293
-54,190
-11% -$638K
SKYE icon
83
Skye Bioscience
SKYE
$9.34M
$4M 0.1%
+62,500
New +$5.93M
TRIB
84
Trinity Biotech
TRIB
$5.96M
$3.83M 0.09%
60,000
– –
IRTC icon
85
iRhythm Holdings
IRTC
$3.69B
$3.79M 0.09%
35,205
-210,000
-86% -$21.5M
LYRA
86
DELISTED
LYRA THERAPEUTICS INC
LYRA
$3.53M 0.09%
255,151
– –
BDSX icon
87
Biodesix
BDSX
$292M
$3.33M 0.08%
+108,694
New +$3.1M
NVNO
88
enVVeno Medical
NVNO
$6.48M
$3.27M 0.08%
17,809
– –
FHTX icon
89
Foghorn Therapeutics
FHTX
$245M
$3.13M 0.08%
+544,000
New +$3.24M
NBTX
90
Nanobiotix
NBTX
$1.79B
$2.78M 0.07%
555,066
– –
FLNA
91
PUT
Filana Therapeutics
FLNA
$33.6M
$2.26M 0.05%
+183,000
New +$3.86M
ABSI icon
92
Absci
ABSI
$1.36B
$2.16M 0.05%
700,000
– –
XBI icon
93
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$2.1M 0.05%
+22,665
New +$2.03M
XFOR icon
94
X4 Pharmaceuticals
XFOR
$359M
$2.06M 0.05%
118,182
– –
FBRX
95
DELISTED
Forte Biosciences
FBRX
$1.75M 0.04%
130,614
– –
RVNC
96
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.54M 0.04%
600,000
– –
GPCR icon
97
Structure Therapeutics
GPCR
$2.78B
$1.37M 0.03%
+34,852
New +$1.43M
NVAX icon
98
PUT
Novavax
NVAX
$1.52B
$1.27M 0.03%
100,000
-600,000
-86% -$6.04M
FATE icon
99
Fate Therapeutics
FATE
$282M
$1.13M 0.03%
+345,575
New +$1.51M
KYTX icon
100
Kyverna Therapeutics
KYTX
$430M
$1.13M 0.03%
150,000
– –
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Perceptive Advisors held 133 positions worth $4.15B, down 27% from $5.72B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors withdrew a net $673M in Q2 2024, closing 23 positions and reducing 31 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Contineum Therapeutics worth $27.6M.

  • Perceptive Advisors's largest Q2 2024 buy was Contineum Therapeutics: 1,566,668 shares worth $27.6M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q2 2024, an estimated $71.4M increase.
  • Perceptive Advisors's biggest Q2 2024 reduction was Medtronic, cutting an estimated $77M.
  • Perceptive Advisors fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $149M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $4.15B portfolio in Q2 2024.
  • Perceptive Advisors opened 21 new positions and closed 23 in Q2 2024.
  • Perceptive Advisors's portfolio value fell 27% quarter-over-quarter to $4.15B.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.